The FDA panel voted 9 to 2 that AMRN should complete an evaluation of the drug’s ability to benefit the heart prior to an approval decision for patients with high triglycerides.
The pre-market low was $1.85
Execution detail:
Date/time | Symbol | Side | Price | Position |
---|---|---|---|---|
2013-10-17 12:00:00 | AMRN | sell | $2.100 | short |
2013-10-17 12:00:00 | AMRN | buy | $1.940 | 0 |
You need to log into your Tradervue account to leave a comment. If you don't have one,
it takes
just a few seconds to sign up, and it's free!